Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity.

Oncoimmunology · 2020 · PMC7028323 · PMID 32117584

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendp = .052so close (0.05 < p ≤ 0.1)

High expression of TIM3 and VISTA showed a trend toward lower rates of SD ≥6 months/PR/CR (0 versus 52% in each case; p = .052) as did CD68 (albeit weaker; 0 versus 50%; p = .113) ( Table 4 ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Moreover, patients with gynecological cancers appear to have numerically higher frequencies of certain cancer-immunity markers when compared to other disease types including high expression of LAG3 (25%), GZMB (25%), IDO1 (31.3%), IL10 (43.8%) and OX40 ligand (62.5%) (though this did not reach statistical significance) (Supplemental Table 3).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.